Low-dose ruxolitinib for graft-versus-host disease prevention in…
Low-dose ruxolitinib dramatically reduced severe graft rejection after transplant, dropping dangerous complications from 37% to 7% with manageable side effects.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Haematopoietic cell transplantation for relapsed or refractory…
Transplant survival has substantially improved over a decade, with two-year survival now reaching 93% for certain blood cancers when caught early.
Early cancer detection or preventionPredicting recurrence of Stage IA lung adenocarcinoma using ctDNA…
A blood test can detect early lung cancer recurrence months before imaging shows it, helping catch returning disease when treatment options are broadest.
Early cancer detection or preventionAnalytical Validation of a Plasma-Based Rapid Liquid Biopsy Assay…
A new blood-based cancer test delivers results in two days instead of weeks, potentially accelerating treatment decisions for cancer patients.
Early cancer detection or preventionUltrasensitive circulating tumor DNA detection improves…
Ultra-sensitive blood tests identify triple-negative breast cancer patients at highest risk after treatment, guiding who needs closer monitoring or intensified therapy.